Wegovy and Ozempic contain semaglutide, but their names do more than identify two packages. Each name points to a particular approved product, indication, presentation and set of instructions. Saying they are the same molecule is correct. Saying they are interchangeable prescriptions skips the information that makes a prescription useful and safe.
This distinction has become more important as semaglutide’s indications and formulations have expanded. A summary written when Wegovy meant only a weekly weight-management injection may now be incomplete. The comparison below uses US labels reviewed on 3 October 2026 and separates them from EU product information.
Start with the condition being treated
In the United States, Ozempic’s May 2026 prescribing information includes improving blood-glucose control in adults with type 2 diabetes. It also includes reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and defined kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. It does not carry the same weight-management indication as Wegovy.
The June 2026 Wegovy label lists long-term weight reduction for specified populations and cardiovascular-risk reduction in adults with established cardiovascular disease and obesity or overweight. The injection also has an accelerated-approval indication for defined noncirrhotic MASH with moderate-to-advanced fibrosis. Tablets have their own adult weight-management and cardiovascular indications. These lists should be read product by product, rather than shortened to one brand being for weight and the other for sugar.
The word ‘accelerated’ also needs context. Wegovy’s MASH indication is based on improvements in MASH and fibrosis, with continued approval potentially dependent on confirming clinical benefit. That is a specific regulatory evidence pathway. It should not be presented as a guarantee that every semaglutide formulation prevents liver-related complications. Nor does a broad discussion of liver health establish that a person has the condition described by the label.
Shared biology does not create shared instructions
Semaglutide is a GLP-1 receptor agonist. The active ingredient helps explain the overlap in adverse effects and precautions. However, a product’s route, device, strength and administration schedule affect its use. A weekly injection and an oral tablet are not related by a simple milligram-for-milligram rule.
Wegovy now has both injectable and oral presentations in the reviewed US label. Ozempic’s reviewed US label concerns injection. Oral Wegovy has fasting and timing requirements that do not apply in the same way to the injection. Devices can differ even within one brand as presentations change. The pharmacist and care team should confirm which presentation was supplied and provide its specific instructions. Oral versus injectable GLP-1 treatment examines these practical differences without supplying a conversion plan.
A prescription name is therefore only the first check. Look at the generic ingredient, the route and the actual packaging. If a dispensing change is unexpected, ask the pharmacist to reconcile it with the prescription before using the product. Do not combine semaglutide products to imitate a different labeled strength. The Wegovy label advises against concurrent use with another semaglutide-containing medicine or another GLP-1 receptor agonist.
Trial results belong to the studied product and population
Trials in people with type 2 diabetes and trials in people with obesity without diabetes do not answer identical questions. Background treatment, glucose control, entry criteria and outcome definitions can differ. A weight-loss figure from one trial should not be attached to both brands merely because semaglutide appears on each label.
Even when a label draws on cardiovascular or weight-management evidence, it specifies the population and intended use. The relevant question is not whether the molecule has ever shown a benefit somewhere. It is whether the proposed treatment has evidence for the intended outcome in a population that informs the current clinical decision. Our semaglutide evidence guide connects the major findings with those limitations.
Consider an article that reports a reduction in heart events and then describes it as a benefit for anyone taking semaglutide. That sentence has dropped the enrollment conditions and changed the endpoint’s scope. The more defensible version names the trial population and then checks the current label. A clinically appropriate decision may involve further judgment, but readers should be able to see where published evidence ends and individual assessment begins.
Similar warnings still need a careful review
Both US labels carry the thyroid C-cell tumor warning. They describe rodent findings and uncertainty about their relevance to humans, with contraindications for personal or family history of medullary thyroid carcinoma or MEN 2. This is not a claim that every thyroid condition has the same implications. The thyroid-warning explainer unpacks that distinction.
Other clinically important concerns include pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration-related kidney problems and effects on other medicines. The risk of low blood glucose can be different when insulin or an insulin secretagogue is also used. People with diabetes and a history of diabetic retinopathy may need particular monitoring. A shared molecule should encourage a careful medication review, not encourage someone to copy another person’s experience.
Pregnancy planning belongs in that review. Semaglutide labels contain a two-month planning interval because the medicine remains in the body for a prolonged period. The appropriate plan also depends on why treatment was prescribed and what condition still needs management. A person using a medicine for diabetes needs a coordinated replacement strategy, rather than simply being told to focus on weight loss. Pregnancy planning discusses the questions to raise early.
Country-specific names can cause avoidable confusion
EMA’s Ozempic record and EMA’s Wegovy record are separate EU authorisations. They should be consulted for EU use rather than importing US age ranges, formulations or additional indications. National availability and reimbursement also need their own checks. Marketing authorisation across the EU is not evidence that a particular local pharmacy has every presentation in stock.
If an online comparison uses a US brand name but cites a European label, find out which claim belongs to which jurisdiction. The broad biology may travel across borders; the authorised indication and supplied product instructions do not automatically do so. Dates matter because an old account may omit a later indication or route.
Questions that resolve the comparison in practice
Ask the prescriber which clinical goal the proposed product addresses, whether it is being used within the local label, and how progress will be assessed. Ask the pharmacist about the exact presentation and where to find its current patient information. If cost or access is a problem, discuss it directly rather than replacing one brand with another independently.
It is reasonable to ask about off-label prescribing, but an off-label decision is a clinician’s use of an approved medicine beyond a particular indication. It does not expand the brand’s formal approval and does not establish that any advertised semaglutide product is equivalent. Product approval, individual prescribing and insurance coverage are separate questions. Keeping them separate makes the shared-molecule fact useful instead of misleading.
